Emily Heikamp, MD, PhD
Residency: Texas Children's Hospital / Baylor College of Medicine
Research Interests: Epigenetics, hematopoiesis, and oncogenic fusion protein biology in pediatric cancer
Emily Heikamp received her MD and PhD from The Johns Hopkins University School of Medicine. She also holds an MSc from Oxford University in the United Kingdom where she studied as a Marshall Scholar. Emily trained in pediatrics at Baylor College of Medicine / Texas Children’s Hospital. As a pediatrics intern, she was elected to The Journal of Pediatrics editorial board, a position which she continues to hold. Emily completed her residency and first year of pediatric hematology-oncology clinical training at Texas Children’s. As a resident at Baylor, she was a member of the Pediatrician-Scientist Training and Development Program, where she spent time in the laboratory studying hematopoiesis, epigenetics, and leukemia with Margaret Goodell. Emily has long-standing interests in hematopoiesis, immunology, and cancer. As an MD-PhD student in the immunology program at Hopkins, she worked with Jonathan Powell to understand how the mTOR pathway regulates T-cell differentiation. Her PhD work led to several publications, including a first-author paper in Nature Immunology and a provisional US patent. As a student at Oxford, she worked with Adrian Harris to study the tole of the Notch signaling pathway in tumor angiogenesis. She also studied B cell development with Garnett Kelsoe as an undergraduate and Howard Hughes Scholar at Duke University. With her enduring passion for basic science and commitment to improving outcomes in high-risk pediatric cancer, Emily was eager to start forging her career as a pediatric oncologist physician-scientist at Dana-Farber/Boston Children’s. The overarching goal of her career is to become an independent investigator and the leader of her own laboratory, with the goal of translating research discoveries to transform clinical practice in pediatric oncology.